Celldex Therapeutics
CLDX
186 hedge funds and large institutions have $2.18B invested in Celldex Therapeutics in 2015 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 75 increasing their positions, 54 reducing their positions, and 30 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
39% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 54
4% less funds holding
Funds holding: 193 → 186 (-7)
10% less capital invested
Capital invested by funds: $2.43B → $2.18B (-$247M)
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
35% less call options, than puts
Call options by funds: $35.7M | Put options by funds: $55.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$48.7M |
| 2 |
TCMG
TSP Capital Management Group
Summit,
New Jersey
|
+$21.5M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$19.9M |
| 4 |
RI
RTW Investments
New York
|
+$12.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$40.2M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$17.8M |
| 3 |
O
OrbiMed
New York
|
-$16.7M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$15.2M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$13.6M |
CLDX Hedge Fund Activity: Q2 2015 in Review
186 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q2 2015, worth a combined $2.18B — down 10% from $2.43B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of CLDX and 23 opened new positions — a net loss of 7 holders — while 54 trimmed existing stakes and 75 added.
The largest buyer was Frontier Capital Management, adding an estimated $48.7M. The largest seller was Millennium Management, cutting an estimated $40.2M.
- 186 institutional investors held Celldex Therapeutics (CLDX) as of Q2 2015, down from 193 in Q1 2015.
- Funds reported $2.18B of Celldex Therapeutics stock for Q2 2015, down 10% quarter-over-quarter.
- 23 funds opened new Celldex Therapeutics positions in Q2 2015 and 30 closed out, a net change of -7 holders.
- The largest Celldex Therapeutics buyer in Q2 2015 was Frontier Capital Management, an estimated $48.7M added.
- The largest Celldex Therapeutics seller in Q2 2015 was Millennium Management, an estimated $40.2M sold.
Based on aggregated 13F filings for Q2 2015.